5 completed, 1 withdrawn. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 5, Withdrawn 1 |
| Phase 2 | 2 | Completed 2 |
Follow cenegermin: new trials by email Literature Review of cenegermin trials Research Report on cenegermin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NGF Treatment for Patients With Neuropathic Corneal Pain Cenegermin-Bkbj - Corneal Disease, Neuropathy | Phase 1 | Withdrawn | Tufts Medical Center | 2022-11-01 | 2023-01-26 | |
| Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers rhNGF 20μg/mL, Placebo - Healthy Volunteers | Phase 1 | Completed | Dompé Farmaceutici S.p.A | 30 | 2018-03-30 | 2023-12-26 |
| Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma rhNGF, Vehicle - Glaucoma | Phase 1 | Completed | Dompé Farmaceutici S.p.A | 60 | 2016-12-01 | 2020-11-25 |
| A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP) rhNGF 60 µg/ml eye drops solution, rhNGF 180 µg/ml eye drops solution, Placebo - Retinitis Pigmentosa | Phase 1 / Phase 2 | Completed | Dompé Farmaceutici S.p.A | 50 | 2014-01-01 | 2024-04-18 |
| Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis. rhNGF 10 μg/ml, rhNGF 20 μg/ml, vehicle - Neurotrophic Keratitis, Keratitis | Phase 1 / Phase 2 | Completed | Dompé Farmaceutici S.p.A | 174 | 2013-01-01 | 2024-04-19 |
| Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers rhNGF 0.5 µg/mL Sentinel, rhNGF 5 µg/mL Sentinel, rhNGF 20 µg/mL Sentinel - Healthy | Phase 1 | Completed | Dompé Farmaceutici S.p.A | 74 | 2012-07-01 | 2024-04-19 |
Cone-Rod Dystrophies (1) · Corneal Diseases (1) · Corneal Ulcer (1) · Glaucoma (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Keratitis (1) · Retinitis Pigmentosa (1)
Dompé Farmaceutici S.p.A (5) · Tufts Medical Center (1)
United States (3) · Italy (2) · United Kingdom (2) · France (1) · Germany (1) · Poland (1) · Spain (1) · Switzerland (1)
Flavio Mantelli, MD, PhD (2) · Ashley Brooks, MBChB (1) · Francesco Sinigaglia, MD (1) · Jeffrey L Goldberg, MD, PhD (1) · Mauro P Ferrari, PharmD (1) · Pedram Hamrah, MD (1) · Pier Adelchi Ruffini, MD (1) · Thierry Kamtchoua, MD (1)